Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,109.14
(
-0.24%
)
US TECH 100
25,918.50
(
-0.14%
)
Dow Jones
49,442.56
(
-0.01%
)
Brent Oil
91.28
(
0.66%
)
Bitcoin
75,637.14
(
-0.34%
)
News Focus
News Focus
Post# of 517461
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

frrol

Send PM Follow Ignore
Followers 96
Posts 12246
Boards Moderated 0
Alias Born 06/06/2014

frrol

Re: Investor2014 post# 379055

Thursday, 10/20/2022 8:41:50 AM

Thursday, October 20, 2022 8:41:50 AM

Post# of 517461
The wording change was not necessary, but is nice to see. Yes likely had to do with aligning to prominent previous trials like lecanemab.

Our endpoint selection was good, in line with regulatory expectations and current AD research norms. Will be great to see what our 2b/3 trial shows. 500+ patients, while relatively small on its own, is reliable enough for the volatility of these endpoints over almost 12 months to show some credible signal.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AVXL News
More AVXL News